SIZE XSSIZE SMSIZE MDSIZE LG

The Role of PARP Inhibitors in Oncology and Combination Therapy

Originally presented at HOPA's 14th Annual Conference, March 2018.

This session will review the use of poly (ADP-ribose) polymerase (PARP) inhibitors in oncology therapy. Key topics include the mechanism of action of PARP inhibitors, clinical trial data that have led to the current U.S. Food and Drug Administration–approved indications, common and important toxicities of this drug class with recommended dose adjustments, and the rationale for choosing a particular PARP inhibitor for a specific patient. Combination therapy with PARP inhibitors will be discussed, as well as suggestions for toxicity management and future directions of PARP inhibitor use.

Speaker

Laura Alwan, PharmD BCOP

Activity type

Patient Management & Therapeutics

Accreditation Statement

logo acpe

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.

This activity has been approved for .1 CEU

This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.

Release Date: September 26, 2018

Expiration Date: March 22, 2021

Member: $25

Non-Member: $35

Purchase Now

xs
sm
md
lg